Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma

被引:1
|
作者
Yoshida, Takashi [1 ,2 ,3 ,4 ]
Nakamoto, Takahiro [1 ,5 ]
Atsumi, Naho [4 ,5 ]
Ohe, Chisato [1 ,6 ]
Sano, Takeshi [1 ]
Yasukochi, Yoshiki [7 ]
Tsuta, Koji [4 ,5 ]
Kinoshita, Hidefumi [1 ]
机构
[1] Kansai Med Univ, Dept Urol & Androl, Osaka, Japan
[2] Tottori Univ, Grad Sch Engn, Tottori, Japan
[3] Osaka Saiseikai Noe Hosp, Dept Urol, Osaka, Japan
[4] Kansai Med Univ, Corp Sponsored Res Programs Multicellular Interact, Osaka, Japan
[5] Kansai Med Univ, Dept Pathol, Osaka, Japan
[6] Osaka Metropolitan Univ, Grad Sch Med, Dept Pathol, Osaka, Japan
[7] Kansai Med Univ, Inst Biomed Sci, Dept Genome Anal, Osaka, Japan
基金
日本学术振兴会;
关键词
Immunotherapy; Solid tumor; Immune Checkpoint Inhibitor; co-inhibitory molecule; T-CELLS; EXPRESSION; TIM-3; NIVOLUMAB; RESPONSES; THERAPY; TIGIT;
D O I
10.1136/jitc-2024-009358
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Anti-programmed death-1 (PD-1)/anti-PD-ligand-1 (PD-L1) pathway inhibition is a standard regimen for advanced urothelial carcinoma (UC); however, its limited efficacy has been reflected in reported medium response rates. This study explored the role of next-generation coinhibitory receptors (IRs; lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT)) and their ligands (LGs) in the response to PD-(L)1 blockade therapy and the oncological outcomes in patients with UC.Methods We investigated metastatic UC cases who underwent PD-(L)1 therapy (cohort 1: n=348, cohort 2: n=89, and cohort 4: n=29) or advanced UC cases involving surgery (cohort 3: n=293 and cohort 5: n=90). We assessed the mRNA expression profiles and corresponding clinical information regarding IRs and LGs using cohorts 1, 2, and 3. Additionally, we elucidated the spatial features of these targeted markers using multiplex immunohistochemistry (mIHC) on formalin-fixed paraffin-embedded samples from cohorts 4 and 5. Survival, differential expressed gene, and Gene Set Enrichment analyses were performed. For mIHC, quantitative analyses were also performed to correlate immune and tumor cell densities with patient survival.Results LAG-3 expression was strongly associated with the responsiveness of PD-(L)1 blockade compared with the expression of TIM-3 and TIGIT. In tumors with high LAG-3 levels, the increased expression of fibrinogen-like protein 1 (FGL1) had a significantly negative effect on the response to PD-(L)1 blockade and overall survival. Moreover, high FGL1 levels were associated with elevated CD4+ regulatory T-cell gene signatures and the upregulation of CD39 and neuropilin-1, with both indicating CD8+ T-cell exhaustion. mIHC analyses revealed that patients with stromal CD8+LAG-3+cellshigh-tumor FGL1+cellshigh exhibited a significant negative correlation with survival rates compared with those with stromal CD8+LAG-3+cellshigh-tumor FGL1+cellslow.Conclusions LAG-3 expression and high FGL1 coexpression are important predictive factors of adverse oncological outcomes related to the presence of immunosuppressive contextures. These findings are hypothesis-generating, warranting further mechanistic and clinical studies aimed to evaluate LAG-3/FGL1 blockade in UC.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 28 条
  • [21] The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials
    F. Zhang
    Z. Liu
    J. Liang
    F. Zhang
    K. Wu
    C. Zhou
    Y. Lu
    X. Wang
    Clinical and Translational Oncology, 2020, 22 : 1750 - 1761
  • [22] PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis
    Ghate, Ketan
    Amir, Eitan
    Kuksis, Markus
    Hernandez-Barajas, David
    Rodriguez-Romo, Laura
    Booth, Christopher M.
    Vera-Badillo, Francisco E.
    CANCER TREATMENT REVIEWS, 2019, 76 : 51 - 56
  • [23] The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    Zhang, Yaowen
    Chen, Junru
    Liu, Haoyang
    Dai, Jindong
    Zhao, Junjie
    Zhu, Sha
    Zhang, Xingming
    Liang, Jiayu
    Hu, Xu
    Zhao, Jinge
    Liu, Zhenhua
    Shen, Pengfei
    Sun, Guangxi
    Zeng, Hao
    CANCER TREATMENT REVIEWS, 2024, 129
  • [24] Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
    Bersanelli, Melissa
    Buti, Sebastiano
    Cortellini, Alessio
    Bandini, Marco
    Banna, Giuseppe Luigi
    Pederzoli, Filippo
    Fare, Elena
    Raggi, Daniele
    Giannatempo, Patrizia
    De Giorgi, Ugo
    Basso, Umberto
    Losanno, Tania
    Santini, Daniele
    Mucciarini, Claudia
    Tucci, Marcello
    Tambaro, Rosa
    Farnesi, Azzurra
    Caffo, Orazio
    Veccia, Antonello
    Naglieri, Emanuele
    Briganti, Alberto
    Procopio, Giuseppe
    Pignata, Sandro
    Necchi, Andrea
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
  • [25] The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population
    Souza, Vinicius Carrera
    Monteiro, Fernando Sabino Marques
    Maluf, Fernando Cotait
    Werutsky, Gustavo
    Fabricio, Vanessa de Carvalho
    Gidekel, Rosemarie
    Gandur-Quiroga, Maria Natalia
    Freitas, Marcelo Roberto Pereira
    Luz, Murilo
    Campos-Gomez, Saul
    Rinck Junior, Jose Augusto
    Bastos, Diogo Assed
    Sade, Juan Pablo
    da Trindade, Karine Martins
    Mota, Augusto Cesar de Andrade
    Fernandes, Roni de Carvalho
    Ruiz, Allan Omar Barillas
    Silva, Breno Dauster
    Galvao de Oliveira, Fernando Nunes
    Cutuli, Hernan Javier
    Nogueira, Lucas
    Aceituno, Luis Fernando Garcia
    Fernandez, Mauricio
    Inman, Eva
    Caitano, Manuel
    Herchenhorn, Daniel
    Ardila-Salcedo, Jaime
    Pacheco, Patricia
    de Jesus, Rafaela Gomes
    Goessling, Gustavo
    Soares, Andrey
    Fay, Andre Poisl
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [26] Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
    Malinga, Nonkululeko Z.
    Siwele, Shalete C.
    Steel, Helen C.
    Kwofie, Luyanda L., I
    Meyer, Pieter W. A.
    Smit, Teresa
    Anderson, Ronald
    Rapoport, Bernardo L.
    Kgokolo, Mahlatse C. M.
    TRANSLATIONAL ONCOLOGY, 2022, 19
  • [27] RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma
    Wang, Jiajun
    Zhang, Sihong
    Wang, Ying
    Zhu, Yanjun
    Xu, Xianglai
    Guo, Jianming
    BMC UROLOGY, 2024, 24 (01)
  • [28] A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation
    Grassi, Pierre
    Hilgers, Werner
    Boissier, Romain
    Bertucci, Alexandre
    Bruyat, Damien
    Duffaud, Florence
    Enoch, Faustine
    Rochigneux, Philippe
    Mancini, Julien
    Deville, Jean-Laurent
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)